Flow cytometric analysis of benign and malignant tumors

流式细胞术单位为NCI临床方案提供广泛的支持，为符合NCI临床方案的患者提供白血病和淋巴瘤的诊断测试，或接受测试以确定是否符合所述方案。流式细胞仪单元提供对NCI和NIH患者的血液、骨髓、细针抽吸物、组织活检和体液的临床流式细胞仪评估。流式细胞术单位进行的大多数流式细胞仪测试涉及检测微小残留疾病(患者在加入NCI方案之前是在外部机构接受治疗后的状态)，以及作为登记临床方案所必需的特定肿瘤细胞特性的测量。该单位致力于提供商业实验室或其他学术机构不提供的许多独特的协议规定的分析。流式细胞术股还积极参与对国家卫生研究院工作人员和广大医学界的教育，使其了解流式细胞术在医疗实践中的适当用途。流式细胞术股还继续支持CCR艾滋病毒和艾滋病恶化科正在进行的研究，包括用流式细胞仪检测与艾滋病毒有关的恶性肿瘤，如原发渗出性淋巴瘤、与HHV8相关的B细胞淋巴瘤或淋巴增生性疾病。

The Flow Cytometry Unit provides extensive support for NCI clinical protocols by providing diagnostic testing for leukemia and lymphoma in patients either on NCI clinical protocols or undergoing testing to determine eligibility for said protocols. The Flow Cytometry Unit provides clinical flow cytometric evaluation of blood, bone marrow, fine needle aspirates, tissue biopsies and body fluids for hematolymphoid neoplasia in NCI and NIH patients. The majority of flow cytometric testing performed by the Flow Cytometry Unit involves detection of minimal residual disease (patients are status post therapy at outside institution prior to enrollment on NCI protocol) and measurement of specific tumor cell characteristics mandated as requisite for enrolment in clinical protocols. Significant effort in the unit is devoted to delivery of numerous unique protocol mandated assays that are not offered by commercial laboratories or other academic institutions. The Flow Cytometry Unit is also actively engaged in education of the NIH staff and medical community at large in the proper utility of flow cytometry in medical practice. The Flow Cytometry Unit also continues to support ongoing research in the CCR HIV and AIDS Malignancy Branch, including flow cytometric detection of HIV-related malignancy such as primary effusion lymphoma, HHV8-associated B-cell lymphoma or lymphoproliferative disorders.